MassHealth drops some obesity drugs July 1
- Massachusetts’ Medicaid program, MassHealth, said anti-obesity drugs including Wegovy, Zepbound and Saxenda will no longer be covered for weight loss starting July 1, 2026. - The cutoff also sweeps in older diet drugs like phentermine and orlistat, while existing prior authorizations submitted before February 17 end June 30. - Massachusetts had tightened GLP-1 access in February after covering them since 2024. (mass.gov)
MassHealth will stop paying for drugs used to treat obesity or overweight on July 1, 2026, including Wegovy, Zepbound, Saxenda and phentermine. (mass.gov) The March 12 MassHealth bulletin says the change applies when those drugs are prescribed for weight loss, and it lists benzphetamine, diethylpropion, Xenical, phendimetrazine, Lomaira, Adipex-P, Wegovy, Zepbound and Saxenda. (mass.gov) MassHealth said prior authorizations submitted before February 17, 2026 will be end-dated on June 30, 2026, and new approvals for obesity or overweight without documented comorbidities will also expire that day. (mass.gov) The cutoff does not end every use of these medicines. MassHealth said GLP-1 and GIP-GLP-1 drugs can still be covered after June 30 for other medically accepted indications, including cardiovascular-risk reduction in adults with body mass index above 27, metabolic dysfunction-associated steatohepatitis, and moderate to severe obstructive sleep apnea in adults with body mass index above 30. (mass.gov) MassHealth had moved in the opposite direction two years earlier. The program began covering anti-obesity medications in January 2024, then made Zepbound a preferred drug in October 2024 and pushed many adult Wegovy and Saxenda patients to switch to Zepbound on January 1, 2025. (mass.gov) It tightened access again on February 17, 2026. Under those rules, adults generally needed a body mass index of at least 35, or lower body mass index thresholds paired with conditions such as uncontrolled hypertension, chronic kidney disease, sleep apnea, prior heart attack or stroke, or liver disease. (mass.gov) The same basic pressure is showing up outside MassHealth: public plans and employers are narrowing coverage even as retail and direct-pay channels expand. Amazon Pharmacy said in March that it would offer Eli Lilly’s Zepbound KwikPen with cash-pay pricing starting at $299 a month for the 2.5 milligram starter dose. (press.aboutamazon.com) Amazon One Medical is also marketing GLP-1 renewals for weight loss and says providers can send prescriptions to a patient’s preferred pharmacy, but its own page says those renewals are not for patients whose prescription requires prior authorization from insurance. (health.amazon.com 1) (health.amazon.com 2) Federal regulators have also signaled a more stable branded supply. The Food and Drug Administration says the tirzepatide injection shortage has been resolved, and in March it approved a higher-dose Wegovy product called Wegovy HD. (fda.gov 1) (fda.gov 2) For MassHealth members, the near-term date is simple: coverage for obesity treatment ends July 1 unless the drug is being used for another approved medical indication. (mass.gov)
